SPDR标普制药指数ETF XPH 深 沪
交易中 07-31 11:10:20 美东时间
42.0799
+0.020
+0.05%
华盛通- 最 高42.1105
- 今 开41.94
- 成交量 3170股
- 最 低 41.727
- 昨 收 42.06
- 总市值 1.54亿
- 52周最高 48.356
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 35.1268
- 委 比 23.08%
- 总股本 365.03万
- 历史最高 59.8943
- 量 比 1.20
- 振 幅 0.91%
- 历史最低 27.4841
- 每 手 1
- 风险率 2.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Top rated and bottom rated stocks according to 3 key drivers of performance – UBS
UBS analysts listed top and bottom-ranked stocks based on a key set of drivers for equities, they named REVS. UBS’s REVS framework consists of elements that are key drivers for equity performance, inc...
07-11 23:33
SA Quant's top healthcare picks amid Q2 earnings season
The Health Care Select Sector SPDR® Fund ETF (NYSEARCA:XLV), which tracks the health care sector, and holds a weightage of 12.12% in the S&P 500 index, fell 0.91% so far this year, compared to 6.78% r...
07-11 21:35
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.
07-11 19:57
Ardelyx spike attributed to Xphozah legal update
Ardelyx (NASDAQ:ARDX) shares rose ~9% on Wednesday, a move Jefferies attributed to a major update related to the company's ongoing legal battle with the U.S. government over Medicare coverage for its ...
07-03 01:38
X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA
X4 Pharmaceuticals announced that the U.S. FDA has granted Fast Track designation to mavorixafor, an oral CXCR4 antagonist, for the treatment of chronic neutropenia (CN). The company is conducting a global Phase 3 trial evaluating mavorixafor in primary CN conditions. Mavorixafor previously received Fast Track designation for WHIM syndrome, which was approved in April 2024. The company aims to complete Phase 3 enrollment by late 2025 and expects ...
06-10 12:00
Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion
Trump signed an executive order to lower drug prices, which could hit pharmacy benefit managers (PBMs) hard. PBMs have come under scrutiny for opaque pricing practices. Mark Cuban calls PBMs a racket.
05-19 15:50
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks
Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.
05-09 00:08
ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot
Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength.
04-19 01:21
Biopharma: A 'Safe Haven' As Tariff Turmoil Rages On?
Biopharma is seen as a safe haven for investors due to its high-margin business model and flexibility in dealing with potential tariffs. Other key questions remain.
04-03 20:25
